Your SlideShare is downloading. ×
Gamal Akabani, PhD.
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Gamal Akabani, PhD.

863
views

Published on

Published in: Technology, Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
863
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Gamal Akabani, PhD. Curriculum Vitae SUMMARY Basic research: I have demonstrated capacity in the basic medical sciences, biomedical engineering, nuclear medicine imaging, nuclear oncology, radiation Monte Carlo transport, radiation oncology, radiotherapy physics, radiobiology, PK/PD and PBPK modeling, basic immunology, and radiopharmaceutical research. I have used in vivo models using ectopic, orthotopic and metastatic tumor animal models to study the spatiotemporal tumor pathophysiology and effect of therapeutics using MR Microscopy, micro-PET, GFP-based imaging, intra-vital microscopy, FACS, microarray analysis, and immunohistochemical techniques. My research has been focused on the development of diagnostic and therapy strategies for the management and treatment of brain tumors using multi-target and combinatorial drugs, including radiolabeled mAb, immuno-toxins, and small MW anti-invasive compounds, capable of modifying the progression and eradication of invasive tumor cells including cancer stem cells. Clinical research: I have over ten years of experience in the development and integration of medical systems for the diagnostic and treatment of cancer. My clinical research experience encompasses the use of single photon emission computer tomography (SPECT), positron emission tomography (PET/CT), MRI, pharmacokinetic modeling, radiation dosimetry, small- scale dosimetry, and morphological microdosimetry of gamma, beta and alpha particle emitting radiolabeled mAbs and compounds for the treatment of cancer using systemic and loco-regional delivery routes. Furthermore, I have extensive experience in the development and execution of clinical trials with radiolabeled monoclonal antibodies for the treatment of Non-Hodgkin’s lymphoma and brain tumors. Of relevance, I carried out the multi-center phase I, II clinical trials of 131 I-labeled 81C6 mAb for the therapy of brain tumors, phase I, II and III clinical trials of 131 I- labeled tositumomab mAb (BEXXAR) (Anti-CD20) for the treatment of NHL, and phase I clinical trial of the alpha particle emitting 211 At-labeled anti-tenascin chimeric 81C6 mAb for the treatment of recurrent brain tumors. EDUCATION:
  • 2. Curriculum Vitae - Gamal Akabani Page 2 Tuesday, July 14, 2009 Ph. D. (Medical Physics), Dept. of Nuclear Engineering, Texas A&M University. College Station, Texas. Dissertation Title: Internal Dosimetry of Electron and Beta Particles. 1990. Advisor: John. W. Poston, Sr. GPA: 3.8. M.S. (Health Physics), Dept. of Nuclear Engineering, Texas A&M University. College Station, Texas. Thesis Title: A Filter for the Compensation of the Angular Dependence of LiF:Mg,Ti for Beta Radiation. 1987. Advisor: John. W. Poston, Sr. GPA: 3.7. B. S. (Physics), National Autonomous University of Mexico. Mexico City. 1985. GPA: 3.8. PROFESSIONAL RECORD: 2008 – Present Associate Professor, Department of Nuclear Engineering, Texas A&MM University, College Station, TX 77840 2007 – 2008 Senior Staff Fellow, Medical Physicist, Food and Drug Administration, Center for Devices and Radiological Health, Office of Device Evaluation, Radiological Devices Branch. Rockville, Maryland. 2005 – 2206 Consultant, Medical Physicist, SAAD Specialist Hospital, Al-Khobar, Saudi Arabia. 1996 – 2005 Assistant Research Professor of Radiology, Department of Radiology, Duke University Medical Center, Durham, North Carolina,. 1995 – 1996 Assistant Professor of Radiation Oncology, Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska. 1990 – 1995 Senior Research Scientist, Pacific Northwest National Laboratory, Medical Dosimetry Section, Richland, Washington. 1989 – 1990 Instructor in Medical Physics, Dept. of Nuclear Engineering, Texas A&M University, College Station, Texas. CONTINUOUS EDUCATION: Oncology and Drug Discovery:  Principles and Applications of DNA Micro-arrays. BIO-TRAC 24. Foundation for Advanced Education in the Sciences (FAES) at the NIH, Bethesda MD, 2008.  Clinical Proteomics and Biomarker Discovery. BIO-TRAC 33. Foundation for Advanced Education in the Sciences (FAES) at the NIH, Bethesda MD. 2008.  Nanotechnology in Medicine. BIO-TRAC 32. Foundation for Advanced Education in the Sciences (FAES) at the NIH, Bethesda MD. 2008.  Stem Cells. BIO-TRAC 18: Foundation for Advanced Education in the Sciences (FAES) at the NIH, Bethesda MD. 2008.  New PET Guidelines for Assessment of Response to Lymphoma Treatment. Medscape CME. 2007.
  • 3. Curriculum Vitae - Gamal Akabani Page 3 Tuesday, July 14, 2009  Imaging X-rays Cause Cancer: A Call to Action for Caregivers and Patients. Medscape CME. 2007.  Biologic Therapies in Oncology: Volume 3. Medscape CME. 2007.  Understanding Pediatric Radiation Therapy. American Association of Physicists in Medicine (AAPM). 2007.  ASH 2006: Lymphoma and Leukemia. Medscape CME. 2006.  The Case for Cure: Promising Chemotherapy Approaches for Patients With Head and Neck Cancer. Medscape CME. 2006.  Making Better Drugs for Children with Cancer. Institute of Medicine. 2005.  The New Oncology: Cost-effectiveness and Matchless Impact of PET-CT in Cancer Management. 2005.  Positron Emission Tomography, University of California, Los Angeles. Ahmanson Biological Imaging Clinic. 2004.  Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis Biological Significanceand Clinical Relevance. Harvard Medical School, Boston, MA, 2002. Medical Physics:  CT Simulation Tools and Technology. American Association of Physicists in Medicine (AAPM). 2006.  Use of CT and PET in Radiation Therapy. AAPM. 2006  Auger Electron Dosimetry. AAPM. 2006.  Instrumentation for PET Imaging. AAPM. 2006.  Image Reconstruction and Image Fusion (PET/CT). AAPM. 2006.  An Improved Method for Measurement of Gamma Camera Resolution. AAPM. 2006.  Image Fusion in Nuclear Medicine - PET/CT. AAPM. 2006.  Establishing minimum performance standards, calibration intervals and optimal exposure values for a whole breast digital unit. AAPM. 2006  A method for quantifying SPECT uniformity. AAPM. 2006. GRANT AWARDS: Phase II Study of 44Gy from 131 I-labeled chimeric 81C6 mAb for CNS Tumors. David A. Reardon, MD, and G. Akabani, Ph.D. NIH R21 Grant, R21CA10578-01. 2003-2004. Alpha particle radioimmunotherapy of primary and metastatic breast cancer. G. Akabani, Ph.D. Duke Comprehensive Cancer Center Breast SPORE Grants. 2003-2004. Alpha particle anti-vascular therapy of malignant glioma. The Charlotte Geyer Foundation. G. Akabani, Ph.D. Principal Investigator. 2003-2004. SRC on Primary and Metastatic Tumors of the CNS. Core B: Medical Nuclear Physics. G. Akabani, Ph.D. Project Leader. NIH R01 Grant, 5 P50 NS20023. 1998-2005. Small-Scale Dosimetry of Bone Using Histological Imaging. G. Akabani, Ph.D. Principal Investigator. NIH R29, CA70164. 1997-2002. Modeling of Images of the Human Body for Purposes of Radiation Dosimetry. G. Akabani, Ph.D. Principal Investigator. Pacific Northwest Laboratory, Research and Development Grants. 1990-1991.
  • 4. Curriculum Vitae - Gamal Akabani Page 4 Tuesday, July 14, 2009 Considerations of Beta and Electron Transport in Internal Dose Calculations. G. Akabani, Ph.D. Principal Investigator. DOE. 1987-1990. Evaluation of the UD-513A TLD Reader. G. Akabani, Principal Investigator. Panasonic Corp. 1990. Modeling of Images of the Human Body for Applications in Nuclear Medicine and Radiation Therapy. G. Akabani, Principal Investigator. Cray Research Supercomputer Time Grants. 1989-1990. HONORS: 1980 First prize at the IV Cybernetics Fair. UNAM, College of Science and Humanities, Mexico City, Mexico. 1980. 1987 IAEA. International Atomic Energy Agency Fellowship Award, 1986 – 1987. 1990 Alpha Nu Sigma Honor Society (inducted at Texas A&M University). 1990. 2005 Berson-Yalow Award to Micheal R. Zalutsky for best scientific paper at the 54th meeting of the Society of Nuclear Medicine. Toronto, Canada. 2005. SOCIETY MEMBERSHIPS: American Association of Physicists in Medicine (AAPM) IEEE Society of Medical Imaging (IEEE MI) Society of Nuclear Medicine (SNM) European Association of Nuclear Medicine (EANM) Society of Molecular Imaging (SMI) American Association for Cancer Research (AACR) The Scientific Research Society (Sigma Xi Honor Society) JOURNAL REVIEWER: Journal of Nuclear Medicine (JNM) Journals for American Association for Cancer Research (AACR) Cancer Research, Molecular Therapeutics, Clinical Cancer Research Medical Physics Journal of Neuro-Oncology Radiation Protection Dosimetry SPOKEN AND WRITTEN LANGUAGES: Spanish and Arabic PROGRAMING LANGUAGES: FORTRAN 77, 90, 95, C, C++, MATLAB, IDL, MATHEMATICA AND MAPLE PEER REVIEW COMMITTEES: NIH, SBIR and STTR, Study Section in the field of radiation oncology, 2000-2003.
  • 5. Curriculum Vitae - Gamal Akabani Page 5 Tuesday, July 14, 2009 NIH, Radiation Oncology and Biology, Study Section, 2003-2005. NIH, Special Emphasis Panel in New Therapeutics, Study Section, 2004-2005. PATENTS: RADIATION DOSIMETRY AND BLOCKING ANTIBODIES AND METHODS AND USES THEREFORE IN THE TREATMENT OF CANCER. International Application No.: PCT/US2005/04188. (WO/2006/073586). BOOKS AND CHAPTERS: i. AC James, G Akabani, A Birchall, NS Jarvis, JK Briant and JS Durham. Absorbed Fractions for Alpha, Electron and Beta Emission. Annex H. Human Respiratory Tract Model for Radiological Protection. Journal of the ICRP. ICRP Publication 66. 1994. ISBN 0-08-041154-1 ii. JR Johnson and G Akabani. Radical Production in Biological Systems. In: Radiation Damage in DNA: Structure/Function Relationships at Early Times. Eds.: Zimbrick, John D. Fuciarelli, Alfred F. Battelle Press, 1994. ISBN 0-935470-90-5 PUBLICATIONS: 1. Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon Ii JE, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, Wong TZ, Zalutsky MR, Pastan I, Bigner DD. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008. 2. Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon Ii JE, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD. A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008. 3. Michael R. Zalutsky, David A. Reardon, Gamal Akabani, R. Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, II, Roger E. McLendon, Charles N. Pegram, James M. Provenzale, Jennifer A. Quinn, Jeremy N. Rich, James J. Vredenburgh, Annick Desjardins, Sri Guruangan, Sith Sathornsumettee, John H. Sampson, Terence Z. Wong, Xiao-Guang Zhao, and Darell D. Bigner. Clinical Experience with α-Emitting Astatine-211: Treatment of Recurrent Brain Tumor Patients with 211At-labeled Chimeric 81C6 Anti-Tenascin Monoclonal Antibody. J Nuc Med. In press. JNM 2007. 4. Roger E. McLendon, Gamal Akabani, Henry S. Friedman, David A. Reardon, Linda Cleveland, Ilkcan Cokgor, James E. Herndon II, Carol Wikstrand, Susan T. Boulton, Allan H. Friedman, Darell D. Bigner, and Michael R. Zalutsky. Tumor Resection Cavity Administered Iodine-131-Labeled Antitenascin 81C6 Radioimmunotherapy in Patients with Malignant Glioma: Neuropathology Aspects. Nucl Med Biol. 2007 May;34(4):405-13. (First and second authors have equal contribution) 5. Vemulapalli S, Metzler SD, Akabani G, Petry NA, Niehaus NJ, Liu X, Patil NH, Greer KL, Jaszczak RJ, Coleman RE, Dong C, Goldschmidt-Clermont PJ, Chin BB. (2007). "Cell
  • 6. Curriculum Vitae - Gamal Akabani Page 6 Tuesday, July 14, 2009 Therapy in Murine Atherosclerosis: In Vivo Imaging with High-Resolution Helical SPECT." Radiology 242(1): 198-207. 6. Sampson JH, Gamal Akabani, Mitchel S. Berger, R. Edward Coleman, Allan H. Friedman, Henry S. Friedman, Kim Greer, James E. Herndon, Sandeep Kunwar, Steve Marcus, Roger E. McLendon, Alison Paolino, Kara Penne, Neil Petry, James Provenzale, David A. Reardon, Terence Wong, Michael R. Zalutsky, Ira Pastan, Darell D. Bigner. Phase I Study of Intracerebral Infusion of an Epidermal Growth Factor Receptor-Targeted Toxin in Recurrent Malignant Brain Tumors. in press. 7. Sampson JH, Akabani G, Friedman AH, Bigner D, Kunwar S, Berger MS, Bankiewicz KS. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus. 2006 Apr 15;20(4):e14. 8. Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR. Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody Construct Radiolabeled with 131I and Administered into the Surgically Created Resection Cavity of Patients with Malignant Glioma: Phase I Trial Results. J Nucl Med. 2006 Jun;47(6):912-918. 9. Akabani G, Carlin S, Welsh P, Zalutsky MR. In vitro cytotoxicity of 211 At-labeled trastuzumab in human breast cancer cell lines: effects of specific activity and HER2 receptor heterogeneity on survival fraction. Nuc Med and Biol, 2006 April, 33(3):333-347. 10. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006 Jan 1;24(1):115-22. 11. A. T. Yordanov, O. Pozzi, S. Carlin, G. Akabani, B. Wieland and M. R. Zalutsky. Wet harvesting of no-carrier-added 211At from an irradiated 209Bi target for radiopharmaceutical applications. Journal of Radioanalytical and Nuclear Chemistry. 2005, Vol. 262(3), pp: 593- 599. 12. Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for Non-Hodgkin's Lymphoma. Clin Med Res. 2005 Aug;3(3):157-65. 13. Metzler, S.D.; Jaszczak, R.J.; Patil, N.H.; Vemulapalli, S.; Akabani, G.; Chin, B.B. Molecular imaging of small animals with a triple-head SPECT system using pinhole collimation. IEEE Transactions on Medical Imaging, Volume 24(7) 2005:853 – 862. 14. Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP, Provenzale JM, Greer KL, DeLong D, Friedman HS, Friedman AH, Zhao XG, Pegram CN, McLendon RE, Bigner DD, Zalutsky MR. Dosimetry and radiographic analysis in newly diagnosed patients with malignant glioma treated with iodine-131 anti-tenascin monoclonal antibody 81C8 therapy: A phase II clinical study. Journal of Nuclear Medicine, Vol 46 (6): 1042-51, 2005.
  • 7. Curriculum Vitae - Gamal Akabani Page 7 Tuesday, July 14, 2009 15. Boyd M, Mairs RJ, Keith WN, Ross SC, Welsh P, Akabani G, Owens J, Vaidyanathan G, Carruthers R, Dorrens J, Zalutsky MR. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation- mediated bystander effects. J Gene Med. 2004 Aug;6(8):937-47. 16. Rizzieri DA, Akabani G, Zalutsky MR, Coleman RE, Metzler SD, Bowsher JE, Toaso B, Anderson E, Lagoo A, Clayton S, Pegram CN, Moore JO, Gockerman JP, DeCastro C, Gasparetto C, Chao NJ, Bigner DD. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood. 2004 Aug 1;104(3):642-8. (First and second authors have equal contribution) 17. Boskovitz A, Akabani G, Pegram CN, Bigner DD, Zalutsky MR. Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. Nucl Med Biol. 2004 Apr;31(3):345-55. 18. James AC, Birchall A, Akabani G. Comparative dosimetry of BEIR VI revisited. Radiat Prot Dosimetry. 2004;108(1):3-26. 19. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE 2nd, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, Pastan I. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003 Oct;65(1):27-35. 20. S Carlin, G Akabani, MR Zalutsky. In Vitro Cytotoxicity of [211At]astatide and [131I]Iodide to Glioma Tumor Cells Expressing the Sodium Iodide Symporter. J Nucl Med. 2003:44(11):1827-38. 21. G Akabani, S Kennel, MR Zalutsky. Microdosimetry analysis of alpha particle emitting radiotherapeutics using histological images. J Nuc Med, 44(5):792-805, 2003. 22. G. Akabani, McLendon RE. Bigner DD. Zalutsky MR. Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. International Journal of Radiation Oncology, Biology, Physics; 54(4):1259-75, 2002. 23. Misra UK. G. Akabani, Pizzo SV. The role of cAMP-dependent signaling in receptor- recognized forms of alpha 2-macroglobulin-induced cellular proliferation. Journal of Biological Chemistry. 277(39):36509-20, 2002. 24. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD: Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20: 1389–1397, 2002. 25. D. E. González Trotter, R. J. Jaszczak, J. E. Bowsher, G. Akabani, and K. L. Greer. High- Resolution Absolute SPECT Quantitation for I-131 Distributions Used in the Treatment of Lymphoma: A Phantom Study. IEEE Transactions on Nuclear Science 48 (3): 707-714 Part 2, 2001.
  • 8. Curriculum Vitae - Gamal Akabani Page 8 Tuesday, July 14, 2009 26. Cokgor I., G Akabani, H. S. Friedman, A. H. Friedman, M. R. Zalutsky, L. M. Zehngebot, J. M. Provenzale, C. D. Guy, C. J. Wikstrand, D. D. Bigner. Long term response in a patient with neoplastic meningitis secondary to melanoma treated with 131I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab)2: A case study. Cancer, 91(9):1809-1813, 2001. 27. Misra UK, Gawdi G, Akabani G, et al. Cadmium-induced DNA synthesis and cell proliferation in macrophages: the role of intracellular calcium and signal transduction mechanisms. Cell Signal 2002;14:327-340. 28. Sgouros G. Stabin M. Erdi Y. Akabani G. Kwok C. Brill AB. Wessels B. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Medical Physics. 27:2150-2164, 2000. 29. Cokgor I.; Akabani G.; Kuan C.-T.; Friedman H.S.; Friedman A.H.; Coleman R.E.; McLendon R.E.; Bigner S.H.; Zhao X.-G.; Garcia-Turner A.M.; Pegram C.N.; Wikstrand C.J.; Shafman T.D.; Herndon II J.E.; Provenzale J.M.; Zalutsky M.R.; Bigner D.D. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology, 18:3862-3872, 2000. 30. I Cokgor, G Akabani, CJ Wikstrand, MR Zalutsky, HS Friedman, AH Friedman, DD Bigner. Radiolabeled monoclonal antibodies for malignant glioma: an improvement over current therapy?. MEDSCAPE, 2000. 31. Aurlien E. Larsen RH. Akabani G. Olsen DR. Zalutsky MR. Bruland OS. Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma- irradiation: analysis of cell survival and microdosimetry. International Journal of Radiation Biology. 76:1129-41, 2000. 32. G Akabani, I Cokgor, RE Coleman, D González Trotter, TZ Wong, HS Friedman, A Garcia- Turner, JE Herndon II, D DeLong, RE McLendon, XG Zhao, CN Pegram, DD Bigner, MR Zalutsky, Dosimetry and Dose-Response Relationships in Newly Diagnosed Patients with Malignant Glioma Treated with Iodine-131 Anti-Tenascin Monoclonal Antibody 81C8 Therapy. I. J. Rad. Onc. Biol. Phys., 46, 491-499, 2000. 33. RH Larsen, KM Murud, G Akabani, P Hoff, ØS Bruland, MR Zalutsky. 211At- and 131I- Labeled Bisphosphonates with High in vivo Statbility and Bone Accumulation. J. Nuc. Med., 40,1197-1203, 1999. 34. RE McLendon, GE Archer, RH Larsen, G Akabani, DD Bigner, MR Zalutsky. Radiotoxicity of systemically adminstered 211 At-labeled human/mouse chimeric monoclonal antibody: a long- term survival study with histological analysis. I. J. Rad. Onc. Biol. Phys., 45, 491-499, 1999. 35. G Akabani, C J Reist, I Cokgor, A H Friedman, H S Friedman, R E Coleman, X.-G Zhao, D D Bigner, M R Zalutsky. Dosimetry of I-131 labeled 81C6 Monoclonal Antibody Administered into Surgically Created Resection Cavities in Malignant Brain Tumor Patients. J. Nuc. Med. 40,631-8, 1999. 36. MA Morse, RE Coleman, G Akabani, N Niehaus, D Coleman, HK Lyerly. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Research. 59,56-8, 1999.
  • 9. Curriculum Vitae - Gamal Akabani Page 9 Tuesday, July 14, 2009 37. D.D. Bigner; M.T. Brown; A.H. Friedman; R.E. Coleman; G. Akabani, H.S. Friedman; W.L. Thorstad; R.E. McLendon; S.H. Bigner; X.G. Zhao; C.N. Pegram; C.J. Wikstrand; J.E. Herndon 2nd; N.A. Vick; N. Paleologos; I. Cokgor; J.M. Provenzale; M.R. Zalutsky. Iodine- 131-Labeled Anti-Tenascin Monoclonal Antibody 81C6 Treatment of Patients with Recurrent Malignant Gliomas: Phase I Trial Results. J. Clinical Oncology, Vol. 16, No 6, pp: 2202- 2212, 1998. 38. C. J. C. Marriot, W. Thorstad, G. Akabani, M. T. Brown, R. E. McLendon, M. W. Hanson and R. E. Coleman. Locally increased uptake of fluorodeoxyglucose FDG after intracavitary administration of Iodine-131 labeled antibody for primary brain tumors. J. Nuc. Med. 39, 1376-1380, 1998. 39. G. Akabani and M. R. Zalustky. Microdosimetry of At-211 Using Histological Images: Application to Bone Marrow. Rad. Res. 148, 599-607, 1997. 40. R H Larsen, G Akabani, P Welsh and M R Zalutsky. The cytotoxicity and microdosimetry of 211 At-labeled chimeric monoclonal antibodies on human glioma and melanoma cells in vitro. Rad. Res. 149, 155-162 1997. 41. G Akabani, W G Hawkins, M B Eckblade, P K Leichner. Patient Specific Dosimetry Based on Quantitative SPECT Imaging and 3D-DFT Convolution. J. Nuc. Med. 38, 308-314, 1997. 42. P K Leichner, G Akabani, D M Colcher, K A Harrison, W G Hawkins, M B Eckblade, M A Tempero. Patient-Specific Dosimetry of Indium-111 and Yttrium-90-Labeled Monoclonal Antibody CC-49. J. Nuc. Med. 38, 512-516, 1997. 43. A Birchall, N S Jarvis, A C James and G Akabani. Algebraic Functions to Approximate the Fraction of Energy Absorbed by Target Tissues in 1994 ICRP Respiratory Tract Model. National Radiological Protection Board, U.K. NRPB-M573. 1995. 44. G Akabani. Development and Implementation of Digitized Phantoms for use in Nuclear Medicine Procedures. Symposium in Voxel Phantom Development. National Radiological Protection Board (NRPB), United Kingdom, 1995. 45. AC James, G Akabani, A Birchall, NS Jarvis, JK Briant and JS Durham. Absorbed Fractions for Alpha, Electron and Beta Emission. Annex H. Human Respiratory Tract Model for Radiological Protection. ICRP Publication 66. Annals of the ICRP. 1994. 46. HL Atkins, JS Robertson, G Akabani. MIRD Dose Estimate Report No. 17: Radiation Absorbed Dose Estimates from Inhaled 81m Kr Gas in Lung Imaging. Medical Internal Radiation Dose Pamphlet No. 17, J. Nucl. Med. Vol. 34, pp. 1382-1384, 1993. 47. G Akabani. Absorbed Dose Calculations in Haversian Canals for Several Beta-emitter Radionuclides. J. Nucl. Med. Vol. 34, pp. 1361-1366, 1993. 48. G Akabani and JW Poston Sr. Absorbed Dose Calculations to Blood and Blood Vessels for Internally Deposited Radionuclides, J. Nucl. Med. Vol. 32, pp. 830-834, 1991. 49. G Akabani, JW Poston Sr. and WE Bolch. Estimates of Absorbed Fractions in Small Volumes for Selected Radionuclides, J. Nucl. Med. Vol. 32, pp. 835-839, 1991. 50. G Akabani and JW Poston Sr. Reevaluation of S-values Considering Electron Transport, Proceedings of the Fifth International Radiopharmaceutical Dosimetry Symposium, pp. 274- 283. EE Watson and AT Schlafke-Stelson, Eds. CONF-910529. 1991.
  • 10. Curriculum Vitae - Gamal Akabani Page 10 Tuesday, July 14, 2009 51. DM Busche, G Akabani and JW Poston Sr. An Approach to Hot Particle Dosimetry using a Monte Carlo Transport Code, Radiation Protection Management. Vol. 8, No. 5, pp. 51-64, 1991. 52. TA Shearer, G Akabani, WE Bolch, JW Poston, Sr. A Model for Electron and Beta Energy Deposition Within Trabecular Bone, Proceedings of the Fifth International Radiopharmaceutical Dosimetry Symposium, pp. 290-296. EE Watson and AT Schlafke- Stelson, Eds. CONF-910529. 1991. 53. JC Liu, G Akabani, WE Bolch and JW Poston Sr. Internal Beta Dose Calculations Using a Point Kernel Algorithm, Proceedings of the Fifth International Radiopharmaceutical Dosimetry Symposium, pp. 297-308. EE Watson and AT Schlafke-Stelson, Eds. CONF- 910529. 1991. 54. J. Durham, WD Reece, WE Wilson and G Akabani. VARSKIN MOD 2 and SADDE MOD 2: Computer codes for assessing skin dose from skin contamination. US. Nuclear Regulatory Commission. NUREG/CR, 1991. 55. G Akabani and JW Poston Sr. A Filter for the Reduction of the Angular Dependence of LiF:Ti,Mg for Beta Radiation, Radiation Protection Management Vol. 7, No. 3, p. 69, 1989. PRESENTATIONS: 1. Cytotoxicity of astatine 211-labeled trastuzumab in human breast cancer cell lines: effects of specific activity and receptor heterogeneity. Akabani G, Carlin S, Welch P, Zalutsky MR. Journal of Nuclear Medicine 46 (5)Suppl. S MAY 2005. 2. A new in-vivo landmark system for aligning histology, MRI, and PET in small animal imaging. Thies Schroeder, Hong Yuan, James E. Bowsher, Lawrence W. Hedlund, Charles T. Wheeler, Andrea Badea, Gamal Akabani and Mark W. Dewhirst. AACR Meeting Abstracts 2005 2005: 900-d-901. 3. (64)Cu-ATSM microPET imaging of tumor hypoxia in animal tumor models: comparison with hypoxia immunostaining. Hong Yuan, Thies Schroeder, James E. Bowsher, Laurence W. Hedlund, Charles T. Wheeler, Davey B. Daniel, Gamal Akabani and Mark W. Dewhirst. AACR Meeting Abstracts 2005 2005: 1243-b-1244. 4. Results of a phase II study of 131 Iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. J. J. Vredenburgh, D. Reardon, G. Akabani, A. Friedman, H. Friedman, R. McLendon, J. Quinn, J. Rich, M. Zalutsky and D. Bigner. ournal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No 16S (June 1 Supplement), 2005: 1510 5. Phase II study of 131-iodine-labeled antitenascin murine monoclonal antibody 81C6 (M81C6) administered to deliver a targeted dose radiation boost dose of 44 Gy to the surgically created cystic cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. D. Reardon, G. Akabani, A. Friedman, H. Friedman, J. Herndon, R. McLendon, J. Quinn, J. Rich, J. Vredenburgh, K. Penne, J. Sampson, S. Gururangan, T. Shafman, T. Wong, J. Dowell, R. Dunn, M. Badruddoja, A. Desjardins, M. Affronti, D. Allen,
  • 11. Curriculum Vitae - Gamal Akabani Page 11 Tuesday, July 14, 2009 S. Jackson, K. Zeigler, S. Silverman, S. Tourt-Uhlig, R. Coleman, M. Zalutsky, and D. Bigner; Society for Neuro-Oncology Ninth Annual Meeting, October 2004. p: 381. 6. Utilizing MRI information to estimate 18 F-FDG distributions in rat flank tumors. Bowsher, J.E.; Hong Yuan; Hedlund, L.W.; Turkington, T.G.; Akabani, G.; Badea, A.; Kurylo, W.C.; Wheeler, C.T.; Cofer, G.P.; Dewhirst, M.W.; Johnson, G.A.; Nuclear Science Symposium Conference Record, 2004 IEEE Volume 4, 16-22 Oct. 2004 Page(s):2488 - 2492 Vol. 4. 7. A phase II study of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant glioma: dosimetry and radiographic analysis. Gamal Akabani, David A Reardon, R Edward Coleman, Terence Z Wong, Scott D Metzler, James E Bowsher, Daniel P Borboriak, James M Provenzale, Henry S Friedman, Allan H Friedman, Roger E McLendon, Michael R Zalutsky, and Darell D Bigner. JOURNAL OF NUCLEAR MEDICINE 46 (5)Suppl. S May 2005. 8. Clinical outcome and distribution measure of a recombinant chimeric protein composed of transforming growth factor alpha and a mutated Pseudomonas exotoxin (TP-38) via convection-enhanced microinfusion on a phase I study for malignant brain tumor. J. H. Sampson, G. Akabani, G. Archer, M. Berger, A. Friedman, H. S. Friedman, S. Marcus, D. Reardon, D. D. Bigner, I. Pastan. 39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No. 397. 9. Duke Univ Med Ctr, Durham, NC; University of California, San Francisco, San Francisco, CA; IVAX, Miami, FL; Duke Univ Med Ctrr, Durham, NC; National Cancer Institute, Bethesda, MD 10. Convection enhanced delivery of TP-38 immunotoxin for the therapy of brain tumors: assessment of delivery and distribution by means of SPECT and MRI. Akabani G, Metzler S, Reardon DA, Wong T, Bigner DD, and John H. Sampson. JOURNAL OF NUCLEAR MEDICINE 52 (5): 454 Suppl. S MAY 2003. 11. High-resolution absolute SPECT quantitation for I-131 distributions used in the treatment of lymphoma: a phantom study. Gonzalez Trotter, D.E.; Jaszczak, R.J.; Bowsher, J.E.; Akabani, G.; Greer, K.L.; Nuclear Science Symposium Conference Record, 2000 IEEE Volume 3, 15- 20 Oct. 2000 Page(s):18/2 - 18/6. 12. Radioimmunotherapy of Refractory Non-Hodgkin’s Lymphoma with I-131-Labeled Chimeric 81C6 Anti-Tenascin Monoclonal Antibody: Dosimetry Study. Akabani G., Rizzieri D., Coleman R.E., Metzler S.D., Zalutsky M.R., and Bigner D.D. JOURNAL OF NUCLEAR MEDICINE 52 (5): 454 Suppl. S MAY 2002. 13. Alpha particle microdosimetry for 213 Bi and 211 At. Akabani G. 3rd alpha-Immuno-Therapy Symposium, Deutsches Krebsforschungszentrum DKFZ, Heidelberg, Germany, 3 - 4 June 2002 14. Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma (NHL).Rizzieri DA, Akabani G, Coleman RE, Zalutsky MR, Niedzwiecki D, Payne N, Wikstrand C, Bigner DD. BLOOD 98 (11): 4716 Part 2 NOV 16 2001 15. Radioimmunotherapy of recurrent glioma patients using alpha-particle emitting astatine-211 labeled chimeric anti-tenascin monoclonal antibody. Zalutsky MR, Akabani G, Friedman HS,
  • 12. Curriculum Vitae - Gamal Akabani Page 12 Tuesday, July 14, 2009 Cokgor I, Coleman RE, Friedman AH, McLendon RE, Zhao XG, Alston KL, Bigner DD JOURNAL OF NUCLEAR MEDICINE 42 (5): 454 Suppl. S MAY 2001 16. The treatment of recurrent patients with brain tumors treated with iodine 131 anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities: The results of a phase II trial. Cokgor I, Akabani G, Friedman A, Coleman R, Zalutsky M, McLendon R, Bigner S, Xiao-Guang Z, Pegram C, Wikstrand C, Herndon J, Provenzale J, Friedman H, Bigner D. NEUROLOGY 54 (7): A33-A33 Suppl. 3 APR 11 2000 17. Microdosimetry of alpha particle emitting 211 At-labeled MAb using histological images of malignant brain tumors. G Akabani, RE McLendon, DD Bigner and MR Zalutsky. Duke University Medical Center, Durham NC, 27710. Society of Nuclear Medicine 46 Annual Meeting, St. Luis, Missouri, June-4- 7. 18. Astatine-211 labeled chimeric anti-tenascin antibody: Phase I trial in brain tumor resection cavity patients. Zalutsky MR, Akabani G, Cokgor I, Friedman HS, Coleman RE, Friedman AH, McLendon RE, Bigner DD. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 26 (9): PS651 SEP 1999 19. Dosimetry of 131 I-labeled anti-tenascin monoclonal antibody 81C6 in newly diagnosed patient with malignant tumors. G. Akabani, I. Cokgor, R. E. Coleman, D. González Trotter, T. Z. Wong, H. S. Friedman, A. Garcia-Turner, J. E. Herndon II, R. E. McLendon, X.-G. Zhao, C. N. Pegram, D. D. Bigner, M. R. Zalutsky. Proceedings of the Fourth Annual Scientific Meeting of the Society of Neuro-Oncology. Scottsdale, AZ. Nov-18-21. 20. Worsening MR and PET findings do not necessarily indicate tumor progression in patients with resected primary brain tumors undergoing treatment with intracavitary iodine-131- labeled anti-tenascin monoclonal antibody. Provenzale JM, Rodriguez D, Coleman RE, Friedman HS, Akabani G, Cokgor I. RADIOLOGY. 209P: 256 Suppl. S NOV 1998. 21. Radiation dosimetry for patients with recurrent brain tumors treated with 131 I- and 211 At- labeled anti-tenascin monoclonal antibody 81C6. G. Akabani, C.J. Reist, I. Cokgor, A.H. Friedman, H.S. Friedman, X-G. Zhao, R.E. Coleman, D.D. Bigner, M.R. Zalutsky. Proceedings of the Third Annual Scientific Meeting of the Society of Neuro-Oncology. San Francisco, CA. Nov-12-15. 22. Results of a phase I trial of patients with recurrent brain tumors and prior radiation therapy treated with I-131-labeled antitenascin monoclonal antibody 81C6 via surgically created resection cavities. Cokgor I, Akabani G, Brown MT, Friedman AH, Coleman RE, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE, Vick NA, Paleologos N, Zalutsky MR, Bigner DDNEUROLOGY 50 (4): S52005 Suppl. 4 APR 1998 23. Results of dose finding study for compartmental delivery of radiolabeled anti-tenascin monoclonal antibody 81C6 in patients with recurrent malignant gliomas.” J.H.Sampson, A.H. Friedman, R.E. Coleman, G. Akabani, H.S. Friedman, N.A. Vick, N. Paleologos, I. Cokgor, M.R. Zalutsky, D.D. Bigner. Proceedings of the Third Annual Scientific Meeting of the Society of Neuro-Oncology. San Francisco, CA. Nov-12-15. 24. Phase I Trail of Patients with Recurrent Brain Tumors and Prior Radiation Therapy treated with 131 I-labeled Anti-tenascin Monoclonal Antibody 81C6 via Surgically-Created Resection Cavities.” I. Cokgor, G. Akabani, M.T. Brown, A.H. Friedman, R.E. Coleman, H.S.
  • 13. Curriculum Vitae - Gamal Akabani Page 13 Tuesday, July 14, 2009 Friedman, W.L. Thorstad, R.E. McLendon, S.H. Bigner, X.-G. Zhao, C.N. Pegram, C.J. Wikstrand, J.E. Herndon, N.A. Vick, N. Paleologos, M.R. Zalutsky, and D.D. Bigner. Proceedings of ASCO Vol. 17. P: 380a (1998). 25. I-131-LL2 (anti-CD22) radioimmunotherapy (RIT) of refractory non-Hodgkin's lymphoma (NHL): Results of a repetitive dosing trial. Vose J, Colcher D, Bierman P, Leichner P, Akabani G, Harrison K, Hohenstein M, Lesser S, Hammershaimb L, Goldenberg DM, Tempero M, Armitage J. JOURNAL OF NUCLEAR MEDICINE 38 (5): 211-211 Suppl. S MAY 1997 26. Patient dosimetry-individualized [131I] anti-B-1 Mab lymphoma radioimmunotherapy: is it feasible in a multicenter trial?” Wahl RL; Zasadny KS; Gates VR; Akabani G; Britton K; Goris M; Macy D; Nuttall P; SgourosG. Proc Annu Meet Am Soc Clin Oncol 1997. 27. Microdosimetry and small-scale dosimetry of At-211 in bone marrow: An analysis based on histological imaging. Akabani G, Zalutsky MR JOURNAL OF NUCLEAR MEDICINE 38 (5): 963-963 Suppl. S MAY 1997 28. Dosimetry methods for patients with malignant CNS tumors treated with I-131 81C6 via surgically created cystic resection cavity. Akabani G, Thorstad WL, Brown MT, Coleman RE, Zalutsky MR, Bigner DD. JOURNAL OF NUCLEAR MEDICINE 38 (5): 395-395 Suppl. S MAY 1997 29. Wahl RL, Zasadny KS, Gates VR, Akabani G, Britton K, Goris M, Macy D, Nutall P, Sgouros G: Patient Dosimetry-individualized I-131 Anti B-1 MAB Lymphoma Radioimmunotherapy: Is it feasible in a multi-center trial? 1997 ASCO meeting, Poster session. 30. Patient specific dosimetry based on quantitative SPECT imaging and 3D-DFT convolution: A comparison with Monte Carlo transport calculations. Akabani G, Hawkins WG, Eckblade MB, Leichner PK JOURNAL OF NUCLEAR MEDICINE 37 (5): 347-347 Suppl. S MAY 1996 31. Patient-specific dosimetry of In-111-/Y-90-labeled monoclonal antibody CC49. Leichner PK, Akabani G, Colcher DM, Harrison KA, Hawkins WG, BaranowskaKortelywicz J, Eckblade M, Augustine SC, Tempero MA. JOURNAL OF NUCLEAR MEDICINE 37 (5): 350-350 Suppl. S MAY 1996 32. Therapeutic Potential of Yttrium-90 Labeled Human Monoclonal Antibody (90Y-Li-Lo- 16.88) in Patients with head and Neck Squamous Cell Cancer”. P.K. Leichner, D.Lydiatt, W. Lydiatt, D. Colcher, S.Johansson, S. Augustine, J.Baranowska-Kortylewicz, K.A. Harrison, G. Akabani, J.L. Klein, and M.A. Tempero. Sixth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer. Princeton, New Jersey. 33. Therapy of refractory non-Hodgkin's lymphoma (NHL) with I-131-LL2 (anti-CD22) radioimmunotherapy (RIT): Results of a repetitive dosing trial. Vose J, Colcher D, Bierman P, Leichner P, Akabani G, Harrison K, Hohenstein M, Lesser S, Hammershaimb L, Goldenberg DM, Tempero M, Armitage J. BLOOD 88 (10): 2258-2258 Part 1 Suppl. 1 NOV 15 1996 34. Small-scale alpha dosimetry of red bone marrow using histological images. Akabani G, Hawkins WG, Leichner PK JOURNAL OF NUCLEAR MEDICINE 37 (5): 1042-1042 Suppl. S MAY 1996
  • 14. Curriculum Vitae - Gamal Akabani Page 14 Tuesday, July 14, 2009 35. Multicellular Microdosimetry of Alpha Emitting Radionuclides Using Histological Imaging” G. Akabani, P. K. Leichner, M. H. Schneiderman. Radiation Research Society (RRS) Annual Meeting Chicago, IL 36. Intercomparison of Personal Dosimeters Used in U.S. Department of Energy Accelerator Facilities” J.C. McDonald, G. Akabani, RM. Loesch, M. Höfert and C. Vaerman International Radiation Protection Association (IRPA). Vienna, Austria 37. Localized Beta Dosimetry of Bone Marrow Using Histological Images” G. Akabani. American Association of Physicist in Medicine (AAPM) Annual Meeting. Boston, Mass. 38. Localized Alpha Dosimetry of Red Bone Marrow Using a Two-Dimensional Monte Carlo Code and Histological Images” G. Akabani. American Association of Physicist in Medicine (AAPM) Annual Meeting, Boston, Mass. 39. Third Intercomparison of DOE High-Energy Neutron Personnel Dosimeters” J. C. McDonald, G. Akabani, R. Loesch. Health Physics Society (HPS) Annual Meeting. Boston, Mass. 40. Development and Implementation of Digitized Phantoms for use in Nuclear Medicine Procedures” G. Akabani Symposium in Voxel Phantom Development. National Radiological Protection Board (NRPB), United Kingdom. 1995. PROFESIONAL REFERENCES: Upon Request.